<p>Twist Bioscience Corporation（纳斯达克代码：TWST - 获取免费报告）内部人士 Dennis Cho 于 12 月 22 日（星期一）出售了 324 股该公司的股票。股票以平均价格 34.56 美元出售，总交易额为 11,197.44 美元。出售完成后，该内部人士直接持有公司 144,680 股股票，价值 5,000,140.80 美元。这代表其持股比例减少了 0.22%。该交易已在与 SEC 的法律文件中披露，具体内容可在此链接查看。</p>
<p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
<p>Dennis Cho 最近还进行了以下交易：</p>
<ul>
<li>在 11 月 3 日（星期一），Dennis Cho 出售了 1,019 股 Twist Bioscience 的股票。股票以平均价格 32.08 美元出售，总价值为 32,689.52 美元。</li>
<li>在 10 月 30 日（星期四），Dennis Cho 出售了 6,515 股 Twist Bioscience 的股票。股票以平均价格 31.44 美元出售，总价值为 204,831.60 美元。</li>
<li>在 10 月 6 日（星期一），Dennis Cho 出售了 3,876 股 Twist Bioscience 的股票。股票以平均价格 32.19 美元出售，总价值为 124,768.44 美元。</li>
</ul>
<h2>Twist Bioscience 股价下跌 3.5%</h2>
<p>纳斯达克：TWST 周二下跌 1.22 美元，报 33.84 美元。该股票交易量为 804,463 股，而其平均交易量为 1,350,107 股。该股票的 50 日移动平均线为 31.02 美元，200 日移动平均线为 31.19 美元。该公司的市值为 20.7 亿美元，市盈率为-25.83，贝塔值为 2.24。公司当前比率为 3.64，速动比率为 3.33，债务与股本比率为 0.03。Twist Bioscience Corporation 的 52 周低点为 23.30 美元，52 周高点为 55.33 美元。</p>
<p>Twist Bioscience（纳斯达克：TWST - 获取免费报告）最近于 11 月 14 日（星期五）发布了其财报。公司报告每股收益（EPS）为-0.45 美元，低于分析师一致预期的-0.40 美元，差额为 0.05 美元。该季度的收入为 9901 万美元，而分析师预期为 9740 万美元。Twist Bioscience 的股本回报率为-27.40%，净利润率为-20.63%。整体来看，股票分析师预计 Twist Bioscience Corporation 在当前财政年度的每股收益为-2.12 美元。</p>
<h2>对 Twist Bioscience 的对冲基金看法</h2>
<p>一些机构投资者最近增加或减少了对 TWST 的持股。Quarry LP 在第三季度以约 28,000 美元的价格收购了 Twist Bioscience 的新股份。Smartleaf Asset Management LLC 在第三季度将其在 Twist Bioscience 的持股增加了 70.6%。Smartleaf Asset Management LLC 现在拥有 1,068 股该公司的股票，价值 29,000 美元，此前在上个季度又收购了 442 股。加拿大国家银行 FI 在第三季度以约 46,000 美元的价格收购了 Twist Bioscience 的新头寸。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Twist Bioscience 的持股增加了 15.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 2,315 股该公司的股票，价值 85,000 美元，此前在上个季度又购买了 302 股。最后，Geneos Wealth Management Inc.在第二季度以约 97,000 美元的价格收购了 Twist Bioscience 的新股份。</p>
<h2>分析师评级变动</h2>
<p>一些券商最近对 TWST 发表了评论。Weiss Ratings 在周一的研究报告中重新发布了对 Twist Bioscience 股票的 “卖出（d-）” 评级。Stephens 在 11 月 3 日（星期一）对 Twist Bioscience 进行了覆盖，给予 “增持” 评级和 41.00 美元的目标价。巴克莱在 12 月 15 日（星期一）将 Twist Bioscience 的目标价从 37.00 美元上调至 39.00 美元，并给予该公司 “增持” 评级。最后，Evercore ISI 在 10 月 7 日（星期二）的研究报告中将 Twist Bioscience 的目标价从 46.00 美元下调至 42.00 美元，并对该股票设定了 “跑赢大盘” 的评级。八位研究分析师对该股票给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 44.88 美元。</p>
<p><strong>查看我们关于 Twist Bioscience 的最新研究报告</strong></p>
<h2>关于 Twist Bioscience</h2>
<p>（获取免费报告）</p>
<p>Twist Bioscience Corporation 是一家专注于 DNA 基础产品和解决方案的合成生物学公司。公司成立于 2013 年，总部位于加利福尼亚州南旧金山，开创了一种专有的基于硅的 DNA 合成平台，旨在高通量生产合成基因和寡核苷酸。Twist 利用半导体制造技术，实现了传统方法无法达到的精确、可扩展的 DNA 合成速度和产量。</p>
<p>Twist 的核心产品是其专有平台，能够自动合成定制的 DNA 片段、基因库和长寡核苷酸。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Twist Bioscience</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9VFdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9VFdTVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
<p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Twist Bioscience 并不在名单上。</p>
<p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TWST

<p>Twist Bioscience（纳斯达克代码：TWST）的内部人士 Dennis Cho 于 12 月 22 日出售了 324 股，交易金额为 11,197.44 美元。出售后，Cho 持有 144,680 股，持股比例下降了 0.22%。该交易已在 SEC 备案中披露。该股票下跌了 3.5%，报 33.84 美元。Twist Bioscience 报告第四季度每股亏损 0.45 美元，未能达到预期。分析师对该股票的评级不一，平均目标价为 44.88 美元</p>

<p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 324 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $34.56, for a total transaction of $11,197.44. Following the completion of the sale, the insider directly owned 144,680 shares in the company, valued at $5,000,140.80. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation（纳斯达克代码：TWST - 获取免费报告）内部人士 Dennis Cho 于 12 月 22 日（星期一）出售了 324 股该公司的股票。股票以平均价格 34.56 美元出售，总交易额为 11,197.44 美元。出售完成后，该内部人士直接持有公司 144,680 股股票，价值 5,000,140.80 美元。这代表其持股比例减少了 0.22%。该交易已在与 SEC 的法律文件中披露，具体内容可在此链接查看。</p>
</div><p>Get <strong>Twist Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Twist Bioscience</strong> 的提醒：</p>
</div><p>Dennis Cho also recently made the following trade(s):</p>
<div class="lb-trans"><p>Dennis Cho 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, November 3rd, Dennis Cho sold 1,019 shares of Twist Bioscience stock. The stock was sold at an average price of $32.08, for a total value of $32,689.52.</li>
<li>On Thursday, October 30th, Dennis Cho sold 6,515 shares of Twist Bioscience stock. The shares were sold at an average price of $31.44, for a total value of $204,831.60.</li>
<li>On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total value of $124,768.44.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 3 日（星期一），Dennis Cho 出售了 1,019 股 Twist Bioscience 的股票。股票以平均价格 32.08 美元出售，总价值为 32,689.52 美元。</li>
<li>在 10 月 30 日（星期四），Dennis Cho 出售了 6,515 股 Twist Bioscience 的股票。股票以平均价格 31.44 美元出售，总价值为 204,831.60 美元。</li>
<li>在 10 月 6 日（星期一），Dennis Cho 出售了 3,876 股 Twist Bioscience 的股票。股票以平均价格 32.19 美元出售，总价值为 124,768.44 美元。</li>
</ul>
</div><h2>Twist Bioscience Trading Down 3.5%</h2>
<div class="lb-trans"><h2>Twist Bioscience 股价下跌 3.5%</h2>
</div><p>NASDAQ:TWST traded down $1.22 on Tuesday, hitting $33.84. 804,463 shares of the stock were exchanged, compared to its average volume of 1,350,107. The stock has a fifty day moving average of $31.02 and a 200-day moving average of $31.19. The stock has a market cap of $2.07 billion, a PE ratio of -25.83 and a beta of 2.24. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $55.33.</p>
<div class="lb-trans"><p>纳斯达克：TWST 周二下跌 1.22 美元，报 33.84 美元。该股票交易量为 804,463 股，而其平均交易量为 1,350,107 股。该股票的 50 日移动平均线为 31.02 美元，200 日移动平均线为 31.19 美元。该公司的市值为 20.7 亿美元，市盈率为-25.83，贝塔值为 2.24。公司当前比率为 3.64，速动比率为 3.33，债务与股本比率为 0.03。Twist Bioscience Corporation 的 52 周低点为 23.30 美元，52 周高点为 55.33 美元。</p>
</div><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05). The firm had revenue of $99.01 million for the quarter, compared to analysts' expectations of $97.40 million. Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Twist Bioscience（纳斯达克：TWST - 获取免费报告）最近于 11 月 14 日（星期五）发布了其财报。公司报告每股收益（EPS）为-0.45 美元，低于分析师一致预期的-0.40 美元，差额为 0.05 美元。该季度的收入为 9901 万美元，而分析师预期为 9740 万美元。Twist Bioscience 的股本回报率为-27.40%，净利润率为-20.63%。整体来看，股票分析师预计 Twist Bioscience Corporation 在当前财政年度的每股收益为-2.12 美元。</p>
</div><h2>Hedge Funds Weigh In On Twist Bioscience</h2>
<div class="lb-trans"><h2>对 Twist Bioscience 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in shares of Twist Bioscience during the third quarter valued at about $28,000. Smartleaf Asset Management LLC lifted its stake in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock worth $29,000 after acquiring an additional 442 shares in the last quarter. National Bank of Canada FI acquired a new position in shares of Twist Bioscience in the third quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in Twist Bioscience during the 2nd quarter valued at approximately $97,000.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对 TWST 的持股。Quarry LP 在第三季度以约 28,000 美元的价格收购了 Twist Bioscience 的新股份。Smartleaf Asset Management LLC 在第三季度将其在 Twist Bioscience 的持股增加了 70.6%。Smartleaf Asset Management LLC 现在拥有 1,068 股该公司的股票，价值 29,000 美元，此前在上个季度又收购了 442 股。加拿大国家银行 FI 在第三季度以约 46,000 美元的价格收购了 Twist Bioscience 的新头寸。Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Twist Bioscience 的持股增加了 15.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 2,315 股该公司的股票，价值 85,000 美元，此前在上个季度又购买了 302 股。最后，Geneos Wealth Management Inc.在第二季度以约 97,000 美元的价格收购了 Twist Bioscience 的新股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have recently commented on TWST. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a research note on Monday. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an &#34;overweight&#34; rating and a $41.00 price target for the company. Barclays raised their price objective on Twist Bioscience from $37.00 to $39.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 15th. Finally, Evercore ISI reduced their price objective on Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating on the stock in a research note on Tuesday, October 7th. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $44.88.</p>
<div class="lb-trans"><p>一些券商最近对 TWST 发表了评论。Weiss Ratings 在周一的研究报告中重新发布了对 Twist Bioscience 股票的 “卖出（d-）” 评级。Stephens 在 11 月 3 日（星期一）对 Twist Bioscience 进行了覆盖，给予 “增持” 评级和 41.00 美元的目标价。巴克莱在 12 月 15 日（星期一）将 Twist Bioscience 的目标价从 37.00 美元上调至 39.00 美元，并给予该公司 “增持” 评级。最后，Evercore ISI 在 10 月 7 日（星期二）的研究报告中将 Twist Bioscience 的目标价从 46.00 美元下调至 42.00 美元，并对该股票设定了 “跑赢大盘” 的评级。八位研究分析师对该股票给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 44.88 美元。</p>
</div><p><strong>View Our Latest Research Report on Twist Bioscience</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Twist Bioscience 的最新研究报告</strong></p>
</div><h2>About Twist Bioscience</h2>
<div class="lb-trans"><h2>关于 Twist Bioscience</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation 是一家专注于 DNA 基础产品和解决方案的合成生物学公司。公司成立于 2013 年，总部位于加利福尼亚州南旧金山，开创了一种专有的基于硅的 DNA 合成平台，旨在高通量生产合成基因和寡核苷酸。Twist 利用半导体制造技术，实现了传统方法无法达到的精确、可扩展的 DNA 合成速度和产量。</p>
</div><p>At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.</p>
<div class="lb-trans"><p>Twist 的核心产品是其专有平台，能够自动合成定制的 DNA 片段、基因库和长寡核苷酸。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Twist Bioscience</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Twist Bioscience</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TWST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
</div><p>Before you consider Twist Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Twist Bioscience 并不在名单上。</p>
</div><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Twist Bioscience（纳斯达克代码：TWST）的一位内部人士出售了价值 11,197.44 美元的股票